Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia.
Karimah S Bell LynumIbrahim TurkozEdward KimPublished in: Early intervention in psychiatry (2018)
PP3M reduced relapse risk and maintained symptomatic and functional improvements compared with placebo in patients with early illness schizophrenia.